{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:46:39Z","timestamp":1787510799222,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12185-023-03683-y","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:05:01Z","timestamp":1702980301000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma"],"prefix":"10.1007","volume":"119","author":[{"given":"Koji","family":"Yada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"3683_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5581\/1516-8484.20130108","volume":"35","author":"AA Ferreira","year":"2013","unstructured":"Ferreira AA, Leite IC, Bustamante-Teixeira MT, Corr\u00eaa CS, da Cruz DT, Rodrigues Dde O, et al. Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index. (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013;35:314\u20138.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"3683_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","volume":"65","author":"IM Nilsson","year":"1976","unstructured":"Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129\u201335.","journal-title":"Acta Paediatr Scand"},{"key":"3683_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","volume":"14","author":"P De Moerloose","year":"2008","unstructured":"De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14:931\u20138.","journal-title":"Haemophilia"},{"key":"3683_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169880","volume":"12","author":"SB van Os","year":"2017","unstructured":"van Os SB, Troop NA, Sullivan KR, Hart DP. Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients. PLoS ONE. 2017;12: e0169880.","journal-title":"PLoS ONE"},{"key":"3683_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1054-139X(99)00042-7","volume":"26","author":"HA Kyng\u00c4s","year":"2000","unstructured":"Kyng\u00c4s HA, Kroll T, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health. 2000;26:379\u201388.","journal-title":"J Adolesc Health"},{"key":"3683_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1055\/s-0038-1648230","volume":"44","author":"A Coppola","year":"2018","unstructured":"Coppola A, Franchini M, Castaman G, Santagostino E, Santoro C, Santoro RC, et al. Treatment regimens with bypassing agents in patients with hemophilia A and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE). Semin Thromb Hemost. 2018;44:551\u201360.","journal-title":"Semin Thromb Hemost"},{"key":"3683_CR7","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1160\/TH16-01-0049","volume":"116","author":"CE Walsh","year":"2016","unstructured":"Walsh CE, Jim\u00e9nez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116:S10\u20137.","journal-title":"Thromb Haemost"},{"key":"3683_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Med. 2012;18:1570\u20134.","journal-title":"Nature Med"},{"key":"3683_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479","volume":"8","author":"Z Sampei","year":"2013","unstructured":"Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE. 2013;8: e57479.","journal-title":"PLoS ONE"},{"key":"3683_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809\u201318.","journal-title":"N Engl J Med"},{"key":"3683_CR11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim\u00e9nez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127\u201338.","journal-title":"Blood"},{"key":"3683_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811\u201322.","journal-title":"N Engl J Med"},{"key":"3683_CR13","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295\u2013305.","journal-title":"Lancet Haematol"},{"key":"3683_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670","volume":"6","author":"R Yang","year":"2022","unstructured":"Yang R, Wang S, Wang X, Sun J, Chuansumrit A, Zhou J, et al. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost. 2022;6: e12670.","journal-title":"Res Pract Thromb Haemost"},{"key":"3683_CR15","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/jcm10194303","volume":"10","author":"S Levy-Mendelovich","year":"2021","unstructured":"Levy-Mendelovich S, Brutman-Barazani T, Budnik I, Avishai E, Barg AA, Levy T, et al. Real-world data on bleeding patterns of hemophilia a patients treated with emicizumab. J Clin Med. 2021;10:4303.","journal-title":"J Clin Med"},{"key":"3683_CR16","doi-asserted-by":"publisher","first-page":"204062072110324","DOI":"10.1177\/20406207211032452","volume":"12","author":"EC Escuriola","year":"2021","unstructured":"Escuriola EC, Sidonio RF Jr. Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE). Ther Adv Hematol. 2021;12:20406207211032452. https:\/\/doi.org\/10.1177\/20406207211032452.","journal-title":"Ther Adv Hematol"},{"key":"3683_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/hae.14212","volume":"27","author":"M Lewandowska","year":"2021","unstructured":"Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensivetreatment centre in the US. Haemophilia. 2021;27:90\u20139.","journal-title":"Haemophilia"},{"key":"3683_CR18","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1055\/s-0038-1636538","volume":"2","author":"M Noguchi-Sasaki","year":"2018","unstructured":"Noguchi-Sasaki M, Soeda T, Ueyama A, Muto A, Hirata M, Kitamura H, et al. Emicizumab, a bispecific antibody to factors IX\/IXa and X\/Xa, does not interfere with antithrombin or TFPI activity in vitro. TH Open. 2018;2:e96\u2013103.","journal-title":"TH Open"},{"key":"3683_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjh.15525","volume":"183","author":"K Yada","year":"2018","unstructured":"Yada K, Nogami K, Shinozawa K, Kitazawa T, Hattori K, Amano K, et al. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V. Br J Haematol. 2018;183:257\u201366.","journal-title":"Br J Haematol"},{"key":"3683_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hae.13860","volume":"25","author":"PER Ellery","year":"2019","unstructured":"Ellery PER, Hilden I, Thyregod P, Martinez ND, Maroney SA, Gill JC, et al. Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and protein S in people with haemophilia. Haemophilia. 2019;25:1083\u201391.","journal-title":"Haemophilia"},{"key":"3683_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4314\/ahs.v18i3.26","volume":"18","author":"MA Al-Ghamdi","year":"2018","unstructured":"Al-Ghamdi MA, Huwait EA, Kumosani TA, Qari M, Moselhy SS, Kumosani AT. Serum proteins C and S levels as early biomarkers for kidney dysfunction in hemophilic patients. Afr Health Sci. 2018;18:681\u20138.","journal-title":"Afr Health Sci"},{"key":"3683_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183","volume":"88","author":"WC Nichols","year":"1996","unstructured":"Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood. 1996;88:1183\u20137.","journal-title":"Blood"},{"key":"3683_CR23","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1182\/blood.V90.8.3067","volume":"90","author":"C Veer van\u2019t","year":"1997","unstructured":"Veer van\u2019t C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor V (LEIDEN). Blood. 1997;90:3067\u201372.","journal-title":"Blood"},{"key":"3683_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1055\/s-0037-1613824","volume":"83","author":"DH Lee","year":"2000","unstructured":"Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost. 2000;83:387\u201391.","journal-title":"Thromb Haemost"},{"key":"3683_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.thromres.2009.11.003","volume":"125","author":"M Franchini","year":"2010","unstructured":"Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res. 2010;125:119\u201323.","journal-title":"Thromb Res"},{"key":"3683_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","volume":"127","author":"N Uchida","year":"2016","unstructured":"Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127:1633\u201341.","journal-title":"Blood"},{"key":"3683_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0038-1651588","volume":"69","author":"M Shima","year":"1993","unstructured":"Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240\u20136.","journal-title":"Thromb Haemost"},{"key":"3683_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","volume":"26","author":"M Okuda","year":"2004","unstructured":"Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haemat. 2004;26:215\u201323.","journal-title":"Clin Lab Haemat"},{"key":"3683_CR29","first-page":"93","volume":"31","author":"T Tokugawa","year":"2020","unstructured":"Tokugawa T, Ishiguro A, Ohira K, Okamoto K, Sakai M, Suzuki T, et al. Guideline of hemostatic treatments for patients with haemophilia\u2014about usage of emicizumab. J JSTH. 2020;31:93\u2013104.","journal-title":"J JSTH"},{"key":"3683_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood.V83.3.683.683","volume":"83","author":"T Hayashi","year":"1994","unstructured":"Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood. 1994;83:683\u201390.","journal-title":"Blood"},{"issue":"Suppl 1","key":"3683_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12959-016-0109-x","volume":"14","author":"T Miyata","year":"2016","unstructured":"Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? Thromb J. 2016;14(Suppl 1):25.","journal-title":"Thromb J"},{"key":"3683_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147\u201356.","journal-title":"N Engl J Med"},{"key":"3683_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","volume":"116","author":"T Lisman","year":"2010","unstructured":"Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878\u201385.","journal-title":"Blood"},{"key":"3683_CR34","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","volume":"1","author":"M Shima","year":"2017","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891\u20139.","journal-title":"Blood Adv"},{"key":"3683_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000073575","volume":"32","author":"HC Hemker","year":"2002","unstructured":"Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249\u201353.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"3683_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","volume":"112","author":"K Ogiwara","year":"2020","unstructured":"Ogiwara K, Nogami K, Matsumoto N, Noguchi-Sasaki M, Hirata M, Soeda T, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X. Int J Hematol. 2020;112:621\u201330.","journal-title":"Int J Hematol"},{"key":"3683_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jth.15530","volume":"20","author":"J Wan","year":"2022","unstructured":"Wan J, Vadaq N, Konings J, Jaeger M, Kumar V, de Laat B, et al. Kallikrein augments the anticoagulant function of the protein C system in thrombin generation. J Thromb Haemost. 2022;20:48\u201357.","journal-title":"J Thromb Haemost"},{"key":"3683_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/MBC.0000000000001148","volume":"33","author":"N Hashimoto","year":"2022","unstructured":"Hashimoto N, Ogiwara K, Matsumoto T, Furukawa S, Takeyama M, Nogami K. Characterization of thrombophilia-related plasmas evaluated by anticoagulants-mediated thrombin and plasmin generation assays. Blood Coagul Fibrinolysis. 2022;33:327\u201336.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3683_CR39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2017-09-800326","volume":"131","author":"R Prince","year":"2018","unstructured":"Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood. 2018;131:1360\u201371.","journal-title":"Blood"},{"key":"3683_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1613145","volume":"88","author":"J Curvers","year":"2002","unstructured":"Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost. 2002;88:5\u201311.","journal-title":"Thromb Haemost"},{"key":"3683_CR41","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1056\/NEJMoa1201994","volume":"366","author":"Y Miyawaki","year":"2012","unstructured":"Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012;366:2390\u20136.","journal-title":"N Engl J Med"},{"key":"3683_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/ejh.13777","volume":"109","author":"N Hashimoto","year":"2022","unstructured":"Hashimoto N, Ogiwara K, Shimonishi N, Nakagawa T, Nakajima Y, Furukawa S, et al. Screening of the protein C pathway abnormality-related thrombophilia by using thrombomodulin-mediated tissue factor-triggered clot waveform analysis. Eur J Haematol. 2022;109:100\u20138.","journal-title":"Eur J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03683-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T10:31:05Z","timestamp":1706697065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03683-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KY has received grants, personal fees from Chugai Pharmaceutical Co., Ltd. (Chugai) and had taught a course endowed by Shire and Takeda Pharmaceutical Co. KO has received grants, personal fees from Chugai and had taught a course endowed by CSL Behring. NS teaches a course endowed by CSL Behring. YN has received grant from Takeda Pharmaceutical Co. TS is an employee of Chugai, and is an inventor of the patents relating to emicizumab. TK is an employee of Chugai, owns Chugai\u2019s stocks, and is an inventor of the patents relating to emicizumab. KN has received grants, personal fees, non-financial support from Chugai, personal fees from F. Hoffmann-La Roche Ltd., grants, personal fees and non-financial support from Sysmex Co., grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, grants, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A\/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc, and grants and personal fees from Shire Plc, and is an inventor of the patents relating to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}